A Phase III, Randomized, Double-Blind Study of Torivumab Plus Chemotherapy Versus Placebo Plus Chemotherapy in Previously Untreated Advanced Non-Small Cell Lung Cancer · Phase III
SITE011 (ITA) · Dr. Jansen
consented 2022-04-05
Adverse events
Grade 1 Constipation — outcome: RECOVERED/RESOLVED; onset 2022-05-16 (study day 25); relationship: N
Grade 1 Peripheral neuropathy — outcome: RECOVERED/RESOLVED; onset 2022-05-21 (study day 30); relationship: not assessed
Grade 1 Neutropenia — outcome: RECOVERED/RESOLVED; onset 2022-05-27 (study day 36); relationship: N
Grade 3 Vomiting — outcome: RECOVERED/RESOLVED; onset 2022-06-17 (study day 57); relationship: N
Grade 1 Thrombocytopenia — outcome: RECOVERED/RESOLVED; onset 2022-12-13 (study day 236); relationship: not assessed
Grade 2 Peripheral neuropathy — outcome: RECOVERED/RESOLVED; onset 2022-12-31 (study day 254); relationship: not assessed
Grade 2 Peripheral neuropathy — outcome: RECOVERED/RESOLVED; onset 2023-02-18 (study day 303); relationship: not assessed
Grade 2 Alopecia — outcome: RECOVERED/RESOLVED; onset 2023-03-28 (study day 341); relationship: not assessed
Grade 2 Dyspnoea — outcome: RECOVERED/RESOLVED; onset 2023-05-02 (study day 376); relationship: N
Data queries
No data queries.